Table 1.
Baseline clinicopathologic characteristics of patients.
| Variables | n = 955 |
|---|---|
| Gender | |
| Male | 407 (42.6%) |
| Female | 548 (57.4%) |
| Age at surgery, years (IQR) | 61 (56–66) |
| ≤61 | 491 (51.4%) |
| >61 | 464 (48.6%) |
| Smoking history | |
| No | 792 (82.9%) |
| Yes | 163 (17.1%) |
| Extent of surgery | |
| Lobectomy | 863 (90.4%) |
| Sub-lobectomy | 91 (9.5%) |
| Pneumonectomy | 1 (0.1%) |
| Predominant pattern | |
| Lepidic | 302 (31.6%) |
| Acinar/Papillary | 562 (58.8%) |
| Micropapillary/Solid | 59 (6.2%) |
| Others | 32 (3.4%) |
| Tumor size, cm | |
| ≤1.0 | 72 (7.5%) |
| 1.1–2.0 | 468 (49.0%) |
| 2.1–3.0 | 316 (33.1%) |
| 3.1–4.0 | 99 (10.4%) |
| Visceral pleural invasion | |
| Absent | 861 (90.2%) |
| Present | 94 (9.8%) |
| Lymphovascular invasion | |
| Absent | 945 (99.0%) |
| Present | 10 (1.0%) |
| Spread through air space | |
| Absent | 925 (96.9%) |
| Present | 30 (3.1%) |
| Epidermal growth factor receptor mutation | |
| Without | 358 (37.5%) |
| 19-del | 266 (27.9%) |
| L858R | 279 (29.2%) |
| Others | 52 (5.4%) |
| Adjuvant chemotherapy | |
| No | 683 (71.5%) |
| Yes | 272 (28.5%) |
| Pathological stage | |
| IA | 775 (81.2%) |
| IB | 180 (18.8%) |
| Total bilirubin | |
| ≤7.9 | 128 (13.4%) |
| >7.9 | 827 (86.6%) |
| Direct bilirubin | |
| ≤2.9 | 150 (15.7%) |
| >2.9 | 805 (84.3%) |
| Albumin | |
| ≤38 | 175 (18.3%) |
| >38 | 780 (81.7%) |
| Uric acid | |
| ≤325 | 560 (58.6%) |
| >325 | 395 (41.4%) |
| Creatinine | |
| ≤58 | 395 (41.4%) |
| >58 | 560 (58.6%) |
| Lactate dehydrogenase | |
| ≤198 | 838 (87.7%) |
| >198 | 117 (12.3%) |
Data are expressed as n (%) or median (IQR). IQR, interquartile range.